在资源匮乏和COVID-19干扰背景下,延长人乳头瘤病毒疫苗接种间隔方案的潜在益处:一项数学建模分析
研究使用HPV-ADVISE个体传播动态模型,针对印度、越南、乌干达和尼日利亚四个中低收入国家,评估延长人乳头瘤病毒疫苗两剂间隔至5年的方案对宫颈癌发病率和接种效率的影响。模型预测,延长方案在第二剂覆盖率极低时宫颈癌发病率降低71%-78%,仍接近常规两剂方案的79%-86%;若14岁女孩无论接种状态均接种且覆盖率达70%,发病率降低86%-93%,效率高于常规两剂方案。
要点
- 模型预测常规两剂方案100年内宫颈癌发病率降低79%-86%。
- 5年延长方案若第二剂仅给已接种女孩且14岁覆盖率30%,发病率降低71%-78%。
- 14岁无论接种状态均接种且覆盖率70%时,发病率降低86%-93%,效率更高。
核心结论
- 三种担忧不太可能对延长剂量方案的人群影响产生实质性影响。
- 延长剂量方案可能提供与两剂方案相似的宫颈癌发病率降低,同时减少短期所需剂量、更高效利用稀缺资源,并提供5年时间窗口重新评估第二剂的必要性。
研究设计与样本
- 使用HPV-ADVISE个体传播动态模型,模拟多型别人乳头瘤病毒感染和疾病。
- 模型根据印度、越南、乌干达和尼日利亚四个中低收入国家的国家特定数据校准。
- 比较场景为仅女孩9岁两剂接种(九价疫苗、疫苗型效力100%、保护持续时间终身、覆盖率80%)。
- 延长剂量场景中变化第二剂覆盖率、一剂疫苗效力和一剂疫苗保护持续时间。
- 还检查了14岁女孩无论既往接种状态均接种的策略。
主要发现
- 常规两剂方案相比不接种,100年内宫颈癌发病率降低79%-86%(依国家而异)。
- 5年延长方案第二剂仅给9岁已接种女孩,若14岁覆盖率30%,宫颈癌发病率降低71%-78%。
- 14岁无论接种状态均接种且覆盖率70%时,宫颈癌发病率降低86%-93%。
- 延长方案效率高于两剂方案,即使接种覆盖率下降。
关键数值与推荐
- 常规两剂方案:9岁女孩两剂接种,九价疫苗,疫苗型效力100%,保护持续时间终身,覆盖率80%,宫颈癌发病率降低79%-86%。
- 5年延长方案(第二剂仅给已接种女孩,14岁覆盖率30%):宫颈癌发病率降低71%-78%。
- 14岁无论接种状态均接种且覆盖率70%:宫颈癌发病率降低86%-93%。
临床怎么用
- 世界卫生组织战略咨询专家组建议可考虑两剂人乳头瘤病毒疫苗间隔延长至3-5年,以缓解疫苗供应短缺。
- 模型分析显示延长剂量方案可能提供与两剂方案相似的宫颈癌发病率降低,同时减少短期所需剂量并更高效利用稀缺资源。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The WHO Strategic Advisory Group of Experts recommended that an extended interval of 3-5 years between the two doses of the human papillomavirus (HPV) vaccine could be considered to alleviate vaccine supply shortages. However, three concerns have limited the introduction of extended schedules: girls could be infected between the two doses, the vaccination coverage for the second dose could be lower at ages 13-14 years than at ages 9-10 years, and identifying girls vaccinated with a first dose to give them the second dose could be difficult. Using mathematical modelling, we examined the potential effect of these concerns on the population-level impact and efficiency of extended dose HPV vaccination schedules. METHODS: We used HPV-ADVISE, an individual-based, transmission-dynamic model of multitype HPV infection and disease, calibrated to country-specific data for four low-income and middle-income countries (India, Viet Nam, Uganda, and Nigeria). For the extended dose scenarios, we varied the vaccination coverage of the second dose among girls previously vaccinated, the one-dose vaccine efficacy, and the one-dose vaccine duration of protection. We also examined a strategy in which girls aged 14 years were vaccinated irrespective of their previous vaccination status. We used a scenario of girls-only two-dose vaccination at age 9 years (vaccine=9 valent, vaccine-type efficacy=100%, duration of protection=lifetime, and coverage=80%) as our comparator. We estimated two outcomes: the relative reduction in the age-standardised cervical cancer incidence (population-level impact) and the number of cervical cancers averted per 100 000 doses (efficiency). FINDINGS: Our model projected substantial reductions in cervical cancer incidence over 100 years with the two-dose schedule (79-86% depending on the country), compared with no vaccination. Projections for the 5-year extended schedule, in which the second dose is given only to girls previously vaccinated at age 9 years, were similar to the current two-dose schedule, unless vaccination coverage of the second dose is very low (reductions in cervical cancer incidence of 71-78% assuming 30% coverage at age 14 years among girls vaccinated at age 9 years). However, when the dose at age 14 years is given to girls irrespective of vaccination status and assuming high vaccination coverage, the model projected a substantially greater reduction in cervical cancer incidence compared with the current two-dose schedule (reductions in cervical cancer incidence of 86-93% assuming 70% coverage at age 14 years, irrespective of vaccination status). Efficiency of the extended schedule was greater than the two-dose schedule, even with a drop in vaccination coverage. INTERPRETATION: The three concerns are unlikely to have a substantial effect on the population-level impact of extended dose schedules. Hence, extended dose schedules will likely provide similar cervical cancer reductions as two-dose schedules, while reducing the number of doses required in the short-term, providing a more efficient use of scarce resources, and offering a 5-year time window to reassess the necessity of the second dose. FUNDING: WHO, Canadian Institute of Health Research Foundation, Fonds de recherche du Québec-Santé, Digital Research Alliance of Canada, and Bill & Melinda Gates Foundation.
引用
- Bénard É, Drolet M, Laprise JF, et al. Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis. Lancet Glob Health. 2023. PMID: 36521952. doi:10.1016/S2214-109X(22)00475-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。